- Sweeney, Daniel A;
- Tuyishimire, Bonifride;
- Ahuja, Neera;
- Beigel, John H;
- Beresnev, Tatiana;
- Cantos, Valeria D;
- Castro, Jose G;
- Cohen, Stuart H;
- Cross, Kaitlyn;
- Dodd, Lori E;
- Erdmann, Nathan;
- Fung, Monica;
- Ghazaryan, Varduhi;
- George, Sarah L;
- Grimes, Kevin A;
- Hynes, Noreen A;
- Julian, Kathleen G;
- Kandiah, Sheetal;
- Kim, Hannah Jang;
- Levine, Corri B;
- Lindholm, David A;
- Lye, David C;
- Maves, Ryan C;
- Oh, Myoung-Don;
- Paules, Catharine;
- Rapaka, Rekha R;
- Short, Willam R;
- Tomashek, Kay M;
- Wolfe, Cameron R;
- Kalil, Andre C
We performed a secondary analysis of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-2) randomized controlled trial and found that baricitinib was associated with a 50% reduction in secondary infections after controlling for baseline and postrandomization patient characteristics. This finding provides a novel mechanism of benefit for baricitinib and supports the safety profile of this immunomodulator for the treatment of coronavirus disease 2019.
